Molecular expression characteristics confirm the malignancy concealed by morphological alterations in endometrial cancer after fertility-preserving treatment
- 71 Downloads
Fertility-preserving treatment (FPT) has been widely used for young patients with early stage endometrial cancer (EC). However, the literature on the effectiveness and safety of FPT remains controversial. The aim of this study was to investigate malignant transformation in EC after FPT by immunohistochemistry (IHC).
A retrospective analysis of pre- and post-treatment biopsy specimens from 24 patients with grade 1 endometrioid adenocarcinoma (EAC) or complex atypical hyperplasia (CAH) was performed. The expression levels of ARID1A, PTEN, and β-catenin were assessed by IHC.
The protein expression levels of ARID1A, PTEN, and β-catenin were not significantly different between pre- and post-treatment specimens. However, there was a significant difference between pre-treatment and normal specimens as well as between post-treatment and normal specimens. The protein expression of β-catenin was significantly increased in patients with progression compared with those without progression after FPT.
The morphologic normalization of patients with EC after FPT may not be accompanied by the absence of tumor malignancy, and β-catenin may serve as a biomarker for the response to FPT. These results may contribute to a better understanding of the malignant transformation of EC after FPT and the optimization of treatment strategies for young patients with birth plans.
KeywordsEndometrial cancer Fertility-preserving treatment Molecular expression Malignant change
We would like to thank all the clinical researchers and patients for contributing to this study.
ZyL: Hypothesis and project development; TwyH: Data collection, specimen collection, data analysis, and manuscript drafting; LL: Data analysis; EY: Data collection and specimen collection; DN: IHC and RT-PCR.
This study was supported by a grant from the Sichuan Youth Foundation of Science of Technology (Grant number: 2015JQ0026).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the Institutional Ethics Committee of West China Second University Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
As this was a retrospective study, formal consent was not required. However, informed consent was obtained from each patient for specimen collection.
- 2.Gallup DG, Stock RJ (1984) Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64(3):417–420Google Scholar
- 5.Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, Koupolovic J, Ben-Baruch G (2003) Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 102(4):718–725Google Scholar
- 6.Jobo T, Imai M, Kawaguchi M, Kenmochi M, Kuramoto H (2000) Successful conservative treatment of endometrial carcinoma permitting subsequent pregnancy: report of two cases. Eur J Gynaecol Oncol 21(2):119–122Google Scholar
- 7.Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S, Nishimura T, Hiura M, Nakano H, Iwasaka T, Miyazaki K, Kamura T (2001) Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 167(1):39–48CrossRefGoogle Scholar
- 8.Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL (2018) Uterine neoplasms, version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(2):170–199CrossRefGoogle Scholar
- 12.Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207(4):261–266CrossRefGoogle Scholar
- 13.Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT (2017) New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 23(2):232–254Google Scholar
- 15.DeSouza LV, Grigull J, Ghanny S, Dube V, Romaschin AD, Colgan TJ, Siu KW (2007) Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 6(7):1170–1182CrossRefGoogle Scholar
- 20.Aberle H, Butz S, Stappert J, Weissig H, Kemler R, Hoschuetzky H (1994) Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 107(Pt 12):3655–3663Google Scholar
- 23.Ayhan A, Mao TL, Suryo RY, Zeppernick F, Ogawa H, Wu RC, Wang TL, Shih I (2015) Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. J Pathol Clin Res 1(3):186–193CrossRefGoogle Scholar
- 24.Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Sanchez-Verde L, Palacios J, Prat J, Matias-Guiu X (2005) Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 18(5):719–727CrossRefGoogle Scholar
- 25.Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JN, Zweizig SL, Van Le L, Hanjani P, Downey G, Walker JL, Reyes HD, Leslie KK (2014) Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 132(3):585–592CrossRefGoogle Scholar
- 32.Reyes HD, Carlson MJ, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Yang S, Stephan JM, Savage EC, Dai D, Goodheart MJ, Leslie KK (2016) Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Gynecol Oncol 140(1):152–160CrossRefGoogle Scholar
- 33.van Gent MD, Nicolae-Cristea AR, de Kroon CD, Osse EM, Kagie MJ, Trimbos JB, Hazelbag HM, Smit VT, Bosse T (2016) Exploring morphologic and molecular aspects of endometrial cancer under progesterone treatment in the context of fertility preservation. Int J Gynecol Cancer 26(3):483–490CrossRefGoogle Scholar